GlassScriptPhysician profile
John Joseph Digiovanni
NPI 1538422308
$1,912.63
in general payments reported to CMS, 2019-2025
21 companies · $166 in 2025
The $166 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $197 · 2023: $949 · 2024: $600 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,670 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,670.33 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $323.29 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $299.67 | 2023-2024 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $218.38 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $158.36 | 2022-2024 | |
| Pfizer INC. | $125.56 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $118.08 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $106.58 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $104.06 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $92.93 | 2022-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Medtronic, INC. | $85.43 | 2022-2023 | Closurefast, Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $57.54 | 2022-2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Genzyme Corporation | $47.22 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.01 | 2022-2024 | Jardiance |
| Abbott Laboratories | $23.62 | 2023 | Freestyle Libre 2 |
| Dexcom, INC. | $23.40 | 2023 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $18.53 | 2023 | Xarelto |
| Amgen INC. | $18.00 | 2024 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $15.33 | 2023 | Ultomiris |
| Noven Therapeutics, LLC | $15.30 | 2024 | Xelstrym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.87 | 2023 | Xifaxan |
| Mayne Pharma Commercial LLC | $9.47 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Digiovanni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.